Showing all posts written by Alexander Zeng

Alexander Zeng
Alexander Zeng
Alexander D. Zeng practices intellectual property law, with a focus on patent prosecution and litigation in medical device technologies.

Prior to joining the firm, he worked as a research scientist for Dr. Hussein Yasine at USC where he was involved with research on the effect of APOE e4 on brain lipids. He graduated from the University of California Los Angeles with his B.S. in Bioengineering and the University of Southern California with his M.S. in Medical Device and Diagnostic Engineering.

During law school at the University of California Irvine, Alexander was a Research Editor on Law Review and was a member of the UCI Intellectual Property, Art, and Technology clinic where he worked on start-up counseling, trademark prosecution, and fair use analysis for documentary film makers.
EKG Monitor May Be Included in Future Apple Smart Watches

EKG Monitor May Be Included in Future Apple Smart Watches

According to Bloomberg, Apple, Inc. is currently developing an electrocardiogram (also known as an EKG or ECG) feature in its smartwatch products. A report from Bloomberg and other sources have stated that the unit in development requires

FDA Pre-cert Program for Lab-Developed Tests

FDA Pre-cert Program for Lab-Developed Tests

The FDA may begin certifying the laboratories that produce lab-developed tests (“LDTs”) instead of drafting regulatory rules to cover the tests themselves.  The American Clinical Laboratory Association describes LDTs as:

[T]ests

Diabetes Monitoring Technology Moving Toward Consumer Convenience

Diabetes Monitoring Technology Moving Toward Consumer Convenience

The FDA recently approved Abott’s FreeStyle Libre Flash Glucose Monitoring System.  According to Bloomberg, this device marks the first continuous glucose monitoring system that adults can use that does not use diagnosis via taking

Apple, Fitbit Join Pilot Program to Quicken FDA Regulatory Review

On September 26, 2017, the FDA announced that it has chosen nine tech companies to participate in a pilot program (FDA Pre-Cert) to help tech companies bypass some regulations that have hindered health software and products release, Bloomberg